REGENXBIO (RGNX) and Regeneron Pharmaceuticals (REGN) Financial Comparison
REGENXBIO (NASDAQ: RGNX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.
Risk and Volatility
REGENXBIO has a beta of -0.77, meaning that its stock price is 177% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500.
Insider and Institutional Ownership
73.4% of REGENXBIO shares are owned by institutional investors. Comparatively, 67.6% of Regeneron Pharmaceuticals shares are owned by institutional investors. 17.0% of REGENXBIO shares are owned by company insiders. Comparatively, 10.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for REGENXBIO and Regeneron Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Regeneron Pharmaceuticals has a consensus target price of $491.04, indicating a potential upside of 23.55%. Given REGENXBIO’s stronger consensus rating and higher probable upside, equities analysts clearly believe REGENXBIO is more favorable than Regeneron Pharmaceuticals.
Valuation & Earnings
This table compares REGENXBIO and Regeneron Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
Regeneron Pharmaceuticals has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares REGENXBIO and Regeneron Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Regeneron Pharmaceuticals beats REGENXBIO on 8 of the 12 factors compared between the two stocks.
REGENXBIO Company Profile
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.